Bristol-Myers Company

James A Bush

Donald E Nettleton, Jr

William T Bradner

James A Matson

Terrence W Doyle

Richard H Schreiber

Robert W Myllymaki

Koji Tomita

Kin S Lam

Sandra J Hofstead

Salvatore Forenza

David M Balitz

Frances A O'Herron

Stanley W Bray

Kedarcidin is a protein antitumor antibiotic produced by Streptoalloteichus sp. nov. strain L585-6, ATCC 53650. The antibiotic comprises a non-protein chromophore and a single chain polypeptide having 114 amino acid residues.

Antitumor antibiotic kedarcidin

A novel complex designated herein as rigolettone complex is produced by fermentation of Streptomyces aburaviensis strain C-38,242 (ATCC 39290). The complex and its purified bioactive components, jildamycin and mantuamycin, exhibit antitumor activity in mouse tumor systems.

Rigolettone antitumor complex

A new cyclic depsipeptide antitumor antibiotic designated herein as sandramycin is produced by fermentation of a new microorganism, Nocardioides sp. strain C49,009, ATCC 39419. Sandramycin possesses antibacterial activity and inhibits the growth of tumors in experimental animals.

Process for producing antitumor antibiotic compound

Novel antitumor antibiotics designated herein as albacarcins M and V are produced by fermentation of Streptomyces albaduncas strain C-38291 (ATCC 39151). The new antibiotics possess antibacterial activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.

Albacarcins V and M

Antitumor antibiotic compound

A novel antitumor agent designated herein as rebeccamycin is produced by fermentation of Nocardia aerocolonigenes (ATCC 39243). Rebeccamycin and its 5'-N-methyl and 5',2',3',6'-tetraacetate derivatives exhibit activity against experimental animal tumor systems.

Process for producing rebeccamycin

Rebeccamycin and process for its preparation

Antitumor agents albacarcins V and M

A polycyclic antitumor antibiotic designated herein as anandimycin is produced by fermentation of Streptomyces anandii subsp. araffinosus strain C-22,437 (ATCC 31431). Anandimycin possesses antibacterial activity and inhibits the growth of tumors in experimental animals.

Fermentation process for producing anandimycin

A known antibiotic substance designated herein as rachelmycin is produced by fermentation of Streptomyces sp. strain C-329, variant 70 (ATCC 31128) or Streptomyces anandii subsp. arraffinosus strain C-22, 437 (ATCC 31431). Rachelmycin exhibits both antibiotic and antitumor properties.

Fermentation process for making rachelmycin

A novel anthracycline antibiotic complex designated herein as figaroic acid complex is produced by fermentation of Streptosporangium sp. strain C-31,751, A.T.C.C. 31129. Figaroic acid complex inhibits the growth of various microorganisms, e.g., Staphylococcus aureus, exhibits phage inducing properties and inhibits the growth of various tumors in rodents, e.g., Sarcoma 180, L-1210 lymphatic leukemia, B-16 melanoma, Walker 256 carcinosarcoma and P-388 lymphatic leukemia.

Antibiotic complex producing bacterial culture

Antibiotic complex

A novel anthracycline antibiotic complex designated herein as bohemic acid complex is produced by fermentation of Actinosporangium sp. A.T.C.C. 31127. The complex and two bioactive components designated marcellomycin and musettamycin exhibit antibiotic activity and inhibit the growth of various tumor systems in rodents.

Growing community of inventors

Fayetteville, NY, United States of America

James A Bush